Both HIF-1α and pAP-1 c-Jun proteins are key players in cancer cells resistance to anti-angiogenic therapies and activate distinct transcriptional programs that converge to coordinate ECM degradation and metastasis, via MMPs33,53. This evidence concerns the gene HIF1A and cancer.